OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach
The three most common genitourinary malignancies (prostate/kidney/bladder cancers) constitute a substantial proportion of all cancer cases, mainly in the elderly population. Early detection is key to maximizing the patients’ survival, but the lack of highly accurate biomarkers that might be used thr...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/18/13890 |
| _version_ | 1797579759332360192 |
|---|---|
| author | José Pedro Sequeira Daniela Barros-Silva Patrícia Ferreira-Torre Sofia Salta Isaac Braga João Carvalho Rui Freitas Rui Henrique Carmen Jerónimo |
| author_facet | José Pedro Sequeira Daniela Barros-Silva Patrícia Ferreira-Torre Sofia Salta Isaac Braga João Carvalho Rui Freitas Rui Henrique Carmen Jerónimo |
| author_sort | José Pedro Sequeira |
| collection | DOAJ |
| description | The three most common genitourinary malignancies (prostate/kidney/bladder cancers) constitute a substantial proportion of all cancer cases, mainly in the elderly population. Early detection is key to maximizing the patients’ survival, but the lack of highly accurate biomarkers that might be used through non-/minimally invasive methods has impaired progress in this domain. Herein, we sought to develop a minimally invasive test to detect and discriminate among those urological cancers based on miRNAs assessment through ddPCR. Plasma samples from 268 patients with renal cell (RCC; <i>n</i> = 119), bladder (BlCa; <i>n</i> = 73), and prostate (PCa; <i>n</i> = 76) carcinomas (UroCancer group), and 74 healthy donors were selected. Hsa-miR-126-3p, hsa-miR-141-3p, hsa-miR-153-5p, hsa-miR-155-5p, hsa-miR-182-5p, hsa-miR-205-5p, and hsa-miR-375-3p levels were assessed. UroCancer cases displayed significantly different circulating hsa-miR-182-5p/hsa-miR-375-3p levels compared to healthy donors. Importantly, the hsa-miR-155-5p/hsa-miR-375-3p panel detected RCC with a high specificity (80.54%) and accuracy (66.04%). Furthermore, the hsa-miR-126-3p/hsa-miR-375-3p panel identified BlCa with a 94.87% specificity and 76.45% NPV whereas higher hsa-miR-126-3p levels were found in PCa patients. We concluded that plasma-derived miRNAs can identify and discriminate among the main genitourinary cancers, with high analytical performance. Although validation in a larger cohort is mandatory, these findings demonstrate that circulating miRNA assessment by ddPCR might provide a new approach for early detection and risk stratification of the most common urological cancers. |
| first_indexed | 2024-03-10T22:40:42Z |
| format | Article |
| id | doaj.art-ddd6931517e046d0bd220d6e92404e7d |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T22:40:42Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-ddd6931517e046d0bd220d6e92404e7d2023-11-19T11:04:42ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-09-0124181389010.3390/ijms241813890OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based ApproachJosé Pedro Sequeira0Daniela Barros-Silva1Patrícia Ferreira-Torre2Sofia Salta3Isaac Braga4João Carvalho5Rui Freitas6Rui Henrique7Carmen Jerónimo8Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalThe three most common genitourinary malignancies (prostate/kidney/bladder cancers) constitute a substantial proportion of all cancer cases, mainly in the elderly population. Early detection is key to maximizing the patients’ survival, but the lack of highly accurate biomarkers that might be used through non-/minimally invasive methods has impaired progress in this domain. Herein, we sought to develop a minimally invasive test to detect and discriminate among those urological cancers based on miRNAs assessment through ddPCR. Plasma samples from 268 patients with renal cell (RCC; <i>n</i> = 119), bladder (BlCa; <i>n</i> = 73), and prostate (PCa; <i>n</i> = 76) carcinomas (UroCancer group), and 74 healthy donors were selected. Hsa-miR-126-3p, hsa-miR-141-3p, hsa-miR-153-5p, hsa-miR-155-5p, hsa-miR-182-5p, hsa-miR-205-5p, and hsa-miR-375-3p levels were assessed. UroCancer cases displayed significantly different circulating hsa-miR-182-5p/hsa-miR-375-3p levels compared to healthy donors. Importantly, the hsa-miR-155-5p/hsa-miR-375-3p panel detected RCC with a high specificity (80.54%) and accuracy (66.04%). Furthermore, the hsa-miR-126-3p/hsa-miR-375-3p panel identified BlCa with a 94.87% specificity and 76.45% NPV whereas higher hsa-miR-126-3p levels were found in PCa patients. We concluded that plasma-derived miRNAs can identify and discriminate among the main genitourinary cancers, with high analytical performance. Although validation in a larger cohort is mandatory, these findings demonstrate that circulating miRNA assessment by ddPCR might provide a new approach for early detection and risk stratification of the most common urological cancers.https://www.mdpi.com/1422-0067/24/18/13890ddPCRbiomarkerscirculating miRNAsprostate cancerrenal cancerbladder cancer |
| spellingShingle | José Pedro Sequeira Daniela Barros-Silva Patrícia Ferreira-Torre Sofia Salta Isaac Braga João Carvalho Rui Freitas Rui Henrique Carmen Jerónimo OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach International Journal of Molecular Sciences ddPCR biomarkers circulating miRNAs prostate cancer renal cancer bladder cancer |
| title | OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach |
| title_full | OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach |
| title_fullStr | OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach |
| title_full_unstemmed | OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach |
| title_short | OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach |
| title_sort | oncouromir circulating mirnas for detection and discrimination of the main urological cancers using a ddpcr based approach |
| topic | ddPCR biomarkers circulating miRNAs prostate cancer renal cancer bladder cancer |
| url | https://www.mdpi.com/1422-0067/24/18/13890 |
| work_keys_str_mv | AT josepedrosequeira oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT danielabarrossilva oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT patriciaferreiratorre oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT sofiasalta oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT isaacbraga oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT joaocarvalho oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT ruifreitas oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT ruihenrique oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach AT carmenjeronimo oncouromircirculatingmirnasfordetectionanddiscriminationofthemainurologicalcancersusingaddpcrbasedapproach |